Long-Term Outcomes of Stereotactic Radiotherapy for Therapy-Resistant Ventricular Tachycardia A Prospective Observational Study

What this Trial Is About

Researchers are investigating long-term outcomes of stereotactic radiotherapy ablation STAR in patients with therapy-refractory ventricular tachycardia VT. This observational study aims to assess both the effectiveness and safety of STAR over an extended period, addressing the need for long-term data in this patient population. The study is sponsored by Universitaire Ziekenhuizen KU Leuven and focuses on people who have VT that has not responded adequately to other treatments. The treatment involves delivering a single dose of 25 to 32.5 Gy of stereotactic radiotherapy to the heart muscle. Participants eligible for STAR are selected based on multidisciplinary discussions. As an observational cohort study, it follows patients after receiving this therapy without assigning treatments randomly. Participants will be followed for up to 48 months, with assessments at baseline and multiple follow-up points to evaluate changes in VT burden, quality of life, heart function, valve disease progression, coronary artery disease, mortality, and radiotherapy-related toxicity. They will provide written consent and agree to return for regular check-ups during the study period to monitor these outcomes.

Cardiac RadiothErapy for VEntricular Tachycardia II